The company said it received the Certificate of Incorporation and licence from the Dubai Multi Commodities Centre (DMCC) authority on June 12, 2026. The incorporation follows the approval granted by the company’s board of directors on April 30, 2026, for setting up a wholly owned subsidiary in Dubai.
DR LAL PATHLABS FZCO will operate in the diagnostic services sector and intends to make strategic investments in diagnostics and allied activities. The subsidiary will explore potential acquisitions, tie-ups and joint ventures.
Also Read: Dr Lal PathLabs in focus as Citi sees 25% upside; check target price here
Dr Lal PathLabs has subscribed to the entire share capital of the newly incorporated entity, amounting to AED 1,91,35,000, comprising 19,135 shares of AED 1,000 each. The company will hold 100% shareholding in the subsidiary.
The company said the transaction involves cash consideration. Since the disclosure relates to the incorporation of a wholly owned subsidiary, the provisions relating to related-party acquisitions are not applicable.
Last month, Dr Lal PathLabs said it expects revenue growth of 13-15% in the financial year ending March 2027 (FY27), with volumes likely to remain the main driver, according to CEO Shankha Banerjee. The earnings before interest, taxes, depreciation and amortisation (EBITDA) margin for FY27 is expected to be 27-28%.
Also Read: Dr Lal PathLabs Q4 Results: Profit slips 15% despite strong revenue growth; ₹4 dividend announced
Banerjee said there are no plans to raise prices in the near term, even as the company keeps a close watch on cost pressures and external factors. Growth is expected to come from a steady rise in patient and sample volumes.
Dr Lal PathLabs reported volume growth of 5.2% in FY26, while revenue growth for the full year was around 12.2%, supported by a mix of volume gains and improvements in product and geographic mix.
Banerjee indicated that this mix benefit is expected to continue, helping bridge the gap between modest volume growth and the overall revenue guidance. The diagnostic chain’s revenue grew 16.6% to ₹702.7 crore in the March quarter, but net profit declined 15.2% year-on-year to ₹131.3 crore.
Shares of Dr Lal PathLabs Ltd ended at ₹1,601.20, up by ₹7.45, or 0.47%, on the BSE.
Also Read: Dr Lal PathLabs Q3 Results: Net profit drops 6%, revenue up 11%
(Edited by : Jomy Jos Pullokaran)
First Published: Jun 12, 2026 9:19 PM IST
